Neogene Therapeutics develops personalized engineered T cell therapies for a broad spectrum of cancers.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/14/2020 | Series A | $110MM | $xx.xx | $24.16B | Ecor1 Capital, Jeito Capital, Polaris Partners, Pontifax, Syncona, Tpg, Two River, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
8,823,550
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ecor1 Capital, Jeito Capital, Polaris Partners, Pontifax, Syncona, Tpg, Two River, Vida Ventures
|
||||||
05/23/2019 | Series Seed | $15MM | $xx.xx | $3.33B | Tpg, Two River, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
5,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Tpg, Two River, Vida Ventures
|